Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

Therapeutic Potential of Mesenchymal Stem Cells in Pediatric Kidney Disorders: A Comprehensive Review.

Bahroudi M., Moghtaderi M.

Laboratory Study on Chronic Kidney Disease, Acute Kidney Injury, Immune Modulation, published in Health Sci Rep (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Health Sci Rep (2026)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
41669498
DOI
10.1002/hsr2.71769

Abstract (original English)

Kidney diseases in children present significant health challenges, often leading to complications and reduced quality of life. Mesenchymal stem cell (MSC) therapy shows promise for pediatric kidney disorders. This review evaluates current evidence on MSC applications in pediatric nephrology, focusing on mechanisms, delivery methods, and outcomes. We analyzed preclinical and clinical studies of MSC therapy for pediatric acute kidney injury (AKI), chronic kidney disease (CKD), glomerular disorders, and Congenital Anomalies of the Kidney and Urinary Tract (CAKUT), comparing pediatric and adult applications. MSCs exert therapeutic effects through immunomodulation, tissue regeneration, anti-fibrotic activity, and paracrine mechanisms. Different sources (bone marrow, umbilical cord, adipose) show varying efficacy. Delivery methods significantly impact outcomes: intravenous administration is well-tolerated but limited (2%-5% kidney delivery), while local infusion enhances targeting (10%-20%). Clinical studies show improved renal function: decreased creatinine in AKI, reduced albumin-to-creatinine ratio in CKD, and decreased proteinuria in nephrotic syndrome. Pediatric applications differ from adult ones in disease etiology, physiological considerations, therapeutic goals, and safety requirements. MSC therapy shows promising potential for pediatric kidney disorders, with preliminary ev

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research